Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study

References

• Landgren O, Caporaso NE. New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007;21:825–840.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Portlock CS, Qin J, . Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483–3489.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Lowry L, Horwich A, . Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009;27:5390–5396.
   PubMed Web of Science ®Google Scholar
• Rueda Dominguez A, Marquez A, Guma J, . Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798–1804.
   PubMed Web of Science ®Google Scholar
• Silvestri F, Fanin R, Velisig M, . The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Tumori 1994;80:453–458.
   PubMed Web of Science ®Google Scholar
• Bezwoda WR, Dansey R, Bezwoda MA. Treatment of Hodgkin's disease with MOPP chemotherapy: effect of dose and schedule modification on treatment outcome. Oncology 1990;47:29–36.
   PubMed Web of Science ®Google Scholar
• van Rijswijk RE, Haanen C, Dekker AW. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989;7:1776–1782.
   PubMed Web of Science ®Google Scholar
• Landgren O, Algernon C, Axdorph U, . Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003;88:438–444.
   PubMed Web of Science ®Google Scholar
• Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy. Lancet 1993; 342:988.
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, . Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:7614–7620.
   PubMed Web of Science ®Google Scholar
• Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007;18:376–380.
   PubMed Web of Science ®Google Scholar
• Evens AM, Cilley J, Ortiz T, . G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545–552.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma 2008;49:1530–1536.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. Updated 2010/19/09. Available from: www.OpenEpi.com
   Google Scholar
• Kuderer NM, Dale DC, Crawford J, . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–2266.
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, . Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916–1924.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187–3205.
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Alibhai SM, . Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147: 400–411.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Herbst C, Reiser M, . Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;(4):CD003189.
   PubMed Web of Science ®Google Scholar
• Dunlop DJ, Eatock MM, Paul J, . Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) 1998;10:107–114.
   PubMedGoogle Scholar
• Rueda A, Sevilla I, Guma J, . Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. Leuk Lymphoma 2001;41:353–358.
   PubMed Web of Science ®Google Scholar
• Younes A, Fayad L, Romaguera J, . Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 2006;42:2976–2981.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Herigault S, Levame M, . Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med 2003;31:1442–1448.
   PubMed Web of Science ®Google Scholar
• Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974;77:185–197.
   PubMed Web of Science ®Google Scholar
• Adachi K, Suzuki M, Sugimoto T, . Effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin-induced lung injury of varying severity. Toxicol Pathol 2003;31:665–673.
   PubMed Web of Science ®Google Scholar